All In Biotech

Drug Trial Radar · NCT00667823

Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension

Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension

Last checked: Nov 19, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

550

Actual

Start

Oct 17, 2008

Primary completion

Dec 7, 2020

Study completion Dec 7, 2020

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Apr 28, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the AC 055 303/SERAPHIN OL study, which will follow the AC 055 302/SERAPHIN study, will be to assess the long-term safety and tolerability of ACT 064992 in patients with symptomatic PAH.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • MacitentanDrug

    Tablet, oral administration, 10 mg dose once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) up to 28 Days After Study Treatment DiscontinuationTime frame: Up to 28 days after study treatment discontinuation (Up to 12 years)
  2. Number of Participants With Death up to 28 Days After Study Treatment DiscontinuationTime frame: Up to 28 days after study treatment discontinuation (Up to 12 years)
  3. Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs) up to 28 Days After Study Treatment DiscontinuationTime frame: Up to 28 days after study treatment discontinuation (Up to 12 years)
  4. Number of Participants With AEs Leading to Permanent Discontinuation of Study TreatmentTime frame: Up to 28 days after study treatment discontinuation (Up to12 years)
  5. Number of Participants With Treatment Emergent Abnormal Liver Tests up to 28 Days After Study Treatment DiscontinuationTime frame: Up to 28 days after study treatment discontinuation (Up to12 years)
  6. Number of Participants With Treatment Emergent Hemoglobin Abnormality up to 28 Days After Study Treatment DiscontinuationTime frame: Up to 28 days after treatment discontinuation (Up to 12 years)

Locations

158 sites in 36 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Arizona Pulmonary Specialists

    Phoenix, Arizona

  • University of California, San Diego

    La Jolla, California

  • GLVA Healthcare Center

    Los Angeles, California

  • Santa Barbara Cottage Hospital

    Santa Barbara, California

  • Liu Center for Pulmonary Hypertension

    Torrance, California

  • University of Colorado CARDIAC AND VASCULAR CENTER

    Aurora, Colorado

  • University of Florida - Division of Pulmonology

    Gainesville, Florida

  • Mayo Clinic, Jacksonville

    Jacksonville, Florida

  • Emory University Hospital - McKelvey Center for Lung Transplantation & Pulmonary Vascular Disease

    Atlanta, Georgia

  • Pulmonary & Critical Care of Atlanta

    Atlanta, Georgia

  • Atlanta Institute for Medical Research

    Decatur, Georgia

  • University of Chicago

    Chicago, Illinois

  • University of Iowa, Pulmonary Hypertension Program

    Iowa City, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Kentuckiana Pulmonary Associate, PLLC

    Louisville, Kentucky

  • Louisiana State University Health Sciences Center

    New Orleans, Louisiana

  • Maine Medical Center

    Portland, Maine

  • University of Maryland School of Medicine; Division of Cardiology

    Baltimore, Maryland

  • Pulmonary/Critical Care Division/Tufts New England Medical Center

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Boston University School of Medicine

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Harper Univ. Hospital/ Wayne State University

    Detroit, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • University of NJ - Robert Wood Johnson Medical School

    New Brunswick, New Jersey

  • Columbia University Medical Center - Pediatric Cardiology

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • University of Cincinnati Ohio Heart Health Center

    Cincinnati, Ohio

  • Ohio State University, Div. of Pul. & Critical Care

    Columbus, Ohio

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Texas Medical Center - St. Paul University

    Dallas, Texas

  • Baylor College of Medicine and the Methodist Hospital,

    Houston, Texas

  • University of Texas Houston Health Center

    Houston, Texas

  • Intermountain Med Ctr- Pulm Dept Heart and Lung Ctr

    Murray, Utah

  • Sentara Hospitals T/A Sentara Cardiovascular Research Intitute

    Norfolk, Virginia

  • Aurora St. Luke's Medical Center

    Milwaukee, Wisconsin

  • Sanatorio MITRE

    Buenos Aires, Argentina

Showing 40 of 158 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.